Please assess the completion status of the following clinical trial:

Trial Title: Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Clinically confirmed cerebellar ataxia with a SARA total score ≥ 3 (range 0-40).~* 2. Clinical diagnosis of probable or possible MSA-C.~* 3. Patients older than 18 years old and younger than 80 years old.~Exclusion Criteria:~* 1. Major systemic diseases such as hepatic, renal or heart failure, malignancy, stroke.~* 2. Concomitant medication which inhibit CYP2C19 enzyme such as Clopidogrel, cimetidine, fluconazole, ketoconazole, voriconazole, etravirine, fluoxetine, fluvoxamine, ticlopidine.~* 3. Pregnancy and/or breastfeeding.~* 4. Acute diseases that might interfere with the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Tllsh2910 to placebo (Type: EXPERIMENTAL): Tllsh2910 160mg per day for 12 weeks with wash-out period 12 weeks and subsequent placebos for 12 weeks.
- Placebo to Tllsh2910 (Type: EXPERIMENTAL): Placebos for 12 weeks with wash-out period 12 weeks and subsequent Tllsh2910 160mg per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).